BAJAJ BROKING

Notification close image
No new Notification messages
card image
Knowledge Realty Trust IPO is Open!
Apply for the Knowledge Realty Trust IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Morepen Laboratories Q1 Results FY25-26: Net Profit at ₹11.41 Cr; Total Income at ₹429.65 Cr

Morepen Laboratories Q1 Results FY25-26: Net Profit at ₹11.41 Cr; Total Income at ₹429.65 Cr

Morepen Laboratories Limited announced its consolidated unaudited financial results for the quarter ended 30 June 2025. The company posted a net profit of ₹11.41 crore in Q1 FY26, down from ₹36.17 crore in the same period last year. Total income for the quarter stood at ₹429.65 crore, compared to ₹458.64 crore in Q1 FY25.

The company reported a decline in net profit, attributed to lower operating income and higher tax provisions, while total income saw a marginal year-on-year dip.

Key Highlights

  • Total Income: ₹429.65 crore in Q1 FY26 vs ₹458.64 crore in Q1 FY25

  • Net Profit: ₹11.41 crore vs ₹36.17 crore YoY

  • Profit Before Tax: ₹15.52 crore vs ₹48.17 crore YoY

  • Total Expenses: ₹414.13 crore

  • EPS: ₹0.20 (Basic & Diluted)

  • Morepen Lab share price: Morepen Lab share price stands at ₹53.07 as of 6th August 2025 (03:15 PM) 

MOREPEN LAB. LTD

Trade

53.37-3.18 (-5.62 %)

Updated - 06 August 2025
57.24day high
DAY HIGH
51.66day low
DAY LOW
5077477
VOLUME (BSE)

Quarterly – Morepen Laboratories Q1 Results FY25-26

Particulars

Q1 FY26

Q1 FY25

Total Income

₹429.65 Cr

₹458.64 Cr

Profit Before Tax

₹15.52 Cr

₹48.17 Cr

Net Profit

₹11.41 Cr

₹36.17 Cr

Total Expenditure

₹414.13 Cr

₹410.48Cr

EPS (Basic & Diluted)

₹0.20

₹0.71

Other Comprehensive Income

₹0.59 Cr

₹2.57 Cr

Total Comprehensive Income

₹11.34  Cr

₹38.74 Cr

Sector Expectations for Morepen Labs Q1 Results FY25-26

  • The pharmaceutical sector was anticipated to post stable to modest growth amid pricing pressure in exports and normalization of domestic demand.

  • API and diagnostics segments were under focus, but seasonal softness was expected in Q1.

  • For Morepen specifically, continued investments in branded and OTC segments were seen as margin-dilutive in the short term.

Management Commentary

There was no official commentary included in the Q1 FY26 result filing. The results indicate a subdued performance driven by elevated expenses and muted revenue growth. Market participants may look ahead to further updates or strategic direction from the management in subsequent quarters.

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Source - Q1 FY25-26 Quarterly Results Uploaded on BSE dated 6th August 2025

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|